Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
277
Completed, industry sponsors, Respiratory, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed277
277 trials
Showing 1 to 25, recently updated first.
AstraZenecaAstraZeneca (AZN)
NCT03953300 · 75 participants · Start Oct 8, 2019 · Primary completion Oct 20, 2026
Drug: Benralizumab; Placebo · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Jacksonville, Florida · 35 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05329194 · 286 participants · Start Apr 29, 2022 · Primary completion Oct 1, 2025
Drug: Tezepelumab · For: Asthma
Sites: Mobile, Alabama; Gilbert, Arizona; Long Beach, California · 37 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00595049 · 11 participants · Start May 31, 2006 · Primary completion Dec 31, 2008
Drug: bosentan · For: Hypertension, Pulmonary
Sites: Camperdown, Australia
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03890666 · 333 participants · Start Oct 26, 2020 · Primary completion Oct 4, 2021
Drug: Albuterol eMDPI DS; albuterol · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Stockton, California · 29 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05535972 · 463 participants · Start Oct 14, 2022 · Primary completion Sep 25, 2023
Drug: FF/UMEC/VI · For: Pulmonary Disease, Chronic Obstructive
Sites: Dongguan, China
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04998604 · 360 participants · Start Sep 27, 2021 · Primary completion Oct 16, 2024
Drug: Dupilumab; Omalizumab and 1 more · For: Chronic Rhinosinusitis With Nasal Polyps; Asthma
Sites: Los Angeles, California; Tampa, Florida; Chicago, Illinois · 87 sites in all
BayerBayer (BAYRY)
NCT02759419 · 18 participants · Start Jun 16, 2016 · Primary completion Sep 15, 2025
Drug: Adempas (Riociguat, BAY63-2521) · For: Hypertension, Pulmonary
Sites: Besançon, France; Brest, France; Le Kremlin-Bicêtre, France · 9 sites in all
Bun Yao Biotechnology Co., LtdIndustry
NCT06828120 · 45 participants · Start Feb 20, 2025 · Primary completion Sep 3, 2025
Drug: Taneasy 600mg granules; Fluimucil 600mg granules · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Taipei, Taiwan
AstraZenecaAstraZeneca (AZN)
NCT06590740 · 1,000 participants · Start Oct 18, 2024 · Primary completion Sep 3, 2025
Drug: Budesonide-Formoterol treatment · For: Cough-Variant Asthma
Sites: Beijing, China; Benxi, China; Chengdu, China · 39 sites in all
- The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04400318 · 109 participants · Start Jun 20, 2020 · Primary completion Jun 26, 2023
Drug: Dupilumab; Placebo · For: Asthma
Sites: Westminster, California; Kansas City, Kansas; Ann Arbor, Michigan · 65 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02310672 · 89 participants · Start Jun 1, 2015 · Primary completion Sep 10, 2019
Drug: Macitentan · For: Pulmonary Arterial Hypertension
Sites: Boston, Massachusetts; Minneapolis, Minnesota; St Louis, Missouri · 41 sites in all
- Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.Pivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03078907 · 108 participants · Start Nov 8, 2017 · Primary completion Feb 10, 2020
Drug: Selexipag; Placebo · For: Pulmonary Arterial Hypertension
Sites: Torrance, California; Atlanta, Georgia; Louisville, Kentucky · 39 sites in all
GlaxoSmithKlineGSK (GSK)
NCT04923347 · 229 participants · Start Jun 6, 2023 · Primary completion Mar 14, 2024
Drug: FF/UMEC/VI · For: Pulmonary Disease, Chronic Obstructive
Sites: Ajmer, India; Bangalore, India; Bikaner, India · 14 sites in all
Bun Yao Biotechnology Co., LtdIndustry
NCT06688292 · 42 participants · Start Sep 20, 2024 · Primary completion Dec 31, 2024
Drug: Taneasy 600mg granules; Actein effervescent 600mg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Taichung, Taiwan
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00433329 · 100 participants · Start Mar 2007 · Primary completion May 2010
Drug: Bosentan; Sildenafil · For: Pulmonary Arterial Hypertension
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01105091 · 30 participants · Start Mar 2010 · Primary completion May 2011
Drug: ACT-385781A (Actelion Epoprostenol); Flolan® · For: Pulmonary Arterial Hypertension
- Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00317486 · 54 participants · Start Sep 2003 · Primary completion Apr 2005
Drug: bosentan · For: Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)Pivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00303459 · 334 participants · Start May 2006 · Primary completion Dec 2013
Drug: bosentan; placebo · For: Pulmonary Arterial Hypertension
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00082186 · 22 participants · Start Jul 2003 · Primary completion Feb 2007
Drug: bosentan · For: Hypertension, Pulmonary
- A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05400369 · 140 participants · Start Aug 10, 2022 · Primary completion Sep 25, 2024
Drug: Sitafloxacin; Moxifloxacin Hydrochloride · For: COPD Exacerbation Acute
Sites: Beijing, China; Changsha, China; Chengdu, China · 18 sites in all
- A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With BenralizumabPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04159519 · 170 participants · Start Jul 27, 2020 · Primary completion Jan 31, 2023
Drug: Symbicort®; Fasenra® and 1 more · For: Asthma; Severe Eosinophilic Asthma
Sites: Brest, France; Dijon, France; Le Kremlin-Bicêtre, France · 23 sites in all
- Phase 4 COPD and Suboptimal Inspiratory Flow RatePivotal-lookingCompleted
Theravance BiopharmaIndustry
NCT05165485 · 404 participants · Start Jan 7, 2022 · Primary completion Nov 13, 2023
Drug: Revefenacin; Tiotropium and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Jasper, Alabama; Phoenix, Arizona; Tucson, Arizona · 76 sites in all
- FAsenra Safety Trial in IndiaCompleted
AstraZenecaAstraZeneca (AZN)
NCT05384938 · 139 participants · Start Nov 19, 2021 · Primary completion Jul 1, 2023
Drug: Benralizumab · For: In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
Sites: Bengaluru, India; Chennai, India; Delhi, India · 13 sites in all
GlaxoSmithKlineGSK (GSK)
NCT04276233 · 100 participants · Start Jun 29, 2021 · Primary completion Oct 28, 2023
Drug: Mepolizumab; Salbutamol · For: Asthma
Sites: Ahmedabad, India; Byculla Mumbai, India; Hyderabad, India · 14 sites in all
- A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04502862 · 202 participants · Start Aug 10, 2020 · Primary completion Oct 3, 2023
Drug: SAR231893; Placebo · For: Asthma
Sites: Bakersfield, California; Culver City, California; Los Angeles, California · 55 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.